ar2065 ARJ Correction <p>Correction: Interleukin-6: a new therapeutic target</p> Smolen S Josef Maini N Ravinder

Professor of Medicine, Chairman Division of Rheumatology, Medical University of Vienna, Vienna, Austria

Emeritus Professor of Rheumatology, The Kennedy Institute of Rheumatology Division, Imperial College, London, UK

 Arthritis Research & Therapy 1478-6354 2006 8 6 407 http://arthritis-research.com/content/8/6/407 10.1186/ar2065 17 10 2006 2006 BioMed Central Ltd

Following the publication of the above article 1, we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows:

JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai; served on an ad hoc advisory board for Roche; and was responsible for the planning and preparation for publication of the Phase II European (CHARISMA) trial of tocilizumab with and without methotrexate. A patent for co-administration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis, of which RNM is named as a co-inventor, has been applied for and fully assigned to Chugai.

 <p>Interleukin-6: a new therapeutic target</p> Smolen JS Maini RN Arthritis Res Ther 2006 8 Suppl 2 S5 10.1186/ar1969 16899109